Barclays analyst Andrew Mok CFA maintains $Tenet Healthcare (THC.US)$ with a buy rating, and adjusts the target price from $171 to $190.
According to TipRanks data, the analyst has a success rate of 42.1% and a total average return of -5.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Tenet Healthcare (THC.US)$'s main analysts recently are as follows:
The outlook for hospitals was exceptionally positive in 2024, and this trend appears set to continue into 2025. There is potential for earnings growth for both HCA and Tenet, provided that the assumptions for organic growth are sensible.
Following Tenet Healthcare's Q3 earnings, revisions to models and detailed earnings assessments for each hospital were noted, with most core adjustments being relatively minor. Changes are primarily driven by the effects of hurricane impacts and updated assumptions regarding Medicaid supplemental payments.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.